Updated recommendations for use of VariZIG - United States, 2013

Morbidity and Mortality Weekly Report

Volumn 62, Issue 28, 2013, Pages 574-576

  Marin, Mona ^a   Bialek, Stephanie R ^a   Seward, Jane F ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; VARICELLA-ZOSTER IMMUNE GLOBULIN;

ARTICLE; CHICKENPOX; HUMAN; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; UNITED STATES;

CHICKENPOX; HUMANS; IMMUNE SERA; IMMUNOLOGIC FACTORS; POST-EXPOSURE PROPHYLAXIS; UNITED STATES;

EID: 84880424372     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Food and Drug Administration. FDA approves VariZIG for reducing chickenpox symptoms. Silver Spring, MD: Food and Drug Administration; 2012. Available at http://www.fda.gov/newsevents/ newsroom/pressannouncements/ucm333233.htm.
2. Cangene Corporation. VariZIG: varicella zoster immune globulin (human). [package insert]. Winnipeg, Canada: Cangene Corporation; 2013.
3. American Academy of Pediatrics. Varicella-zoster infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012:774-89.
4. Brunell PA, Ross A, Miller LH, Kuo B. Prevention of varicella by zoster immune globulin. N Engl J Med 1969;280:1191-4.
5. Brunell PA, Gershon AA, Hughes WT, Riley HD Jr, Smith J. Prevention of varicella in high risk children: a collaborative study. Pediatrics 1972;50:718-22.
6. Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med 1974;290:243-5.
7. Zaia J, Levin MJ, Preblud SK, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983;147:737-43.
8. Levin MJ, Nelson WL, Preblud SR, Zaia JA. Clinical trials with varicellazoster imunoglobulins. In Movell A, Nydegger U, eds. Clinical use of intravenous imunoglobulins. London, UK: Academic Press Inc.; 1986:255-67.
9. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-4).
10. CDC. A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR 2006;55:209-10.
11. CDC. FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR 2012;61:212.
12. Evans EB, Pollock TM, Cradock-Watson JE, Ridehalgh MK. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. Lancet 1980;1:354-6.
13. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Reviews in Medical Microbiology 1993; 4:222-30.
14. Enders G, Miller E. Varicella and herpes zoster in pregnancy and the newborn. In: Arvin A, Gershon A, eds. Varicella-zoster virus: virology and clinical management. Cambridge, UK: Cambridge University Press; 2000.
15. Koren G, Money D, Boucher M, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002;42:267-74.
16. Winsnes R. Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients. Acta Paediatr Scanda 1978;67:77-82.